BACKGROUND: Unnecessary antibiotic use (AU) contributes to increased rates of Clostridioides difficile infection (CDI). The impact of antibiotic restriction on hospital-onset CDI (HO-CDI) has not been assessed in a large group of US acute care hospitals (ACHs). METHODS: We examined cross-sectional and temporal associations between rates of hospital-level AU and HO-CDI using data from 549 ACHs. HO-CDI was defined as a discharge with a secondary International Classification of Diseases, Ninth Revision, Clinical Modification code for CDI (008.45), and treatment with metronidazole or oral vancomycin > 3 days after admission. Analyses were performed using multivariable generalized estimating equation models adjusting for patient and hospital characteristics. RESULTS: During 2006-2012, the unadjusted annual rates of HO-CDI and total AU were 7.3 per 10 000 patient-days (PD) (95% confidence interval [CI], 7.1-7.5) and 811 days of therapy (DOT)/1000 PD (95% CI, 803-820), respectively. In the cross-sectional analysis, for every 50 DOT/1000 PD increase in total AU, there was a 4.4% increase in HO-CDI. For every 10 DOT/1000 PD increase in use of third- and fourth-generation cephalosporins or carbapenems, there was a 2.1% and 2.9% increase in HO-CDI, respectively. In the time-series analysis, the 6 ACHs with a ≥30% decrease in total AU had a 33% decrease in HO-CDI (rate ratio, 0.67 [95% CI, .47-.96]); ACHs with a ≥20% decrease in fluoroquinolone or third- and fourth-generation cephalosporin use had a corresponding decrease in HO-CDI of 8% and 13%, respectively. CONCLUSIONS: At an ecologic level, reductions in total AU, use of fluoroquinolones, and use of third- and fourth-generation cephalosporins were each associated with decreased HO-CDI rates. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
BACKGROUND: Unnecessary antibiotic use (AU) contributes to increased rates of Clostridioides difficile infection (CDI). The impact of antibiotic restriction on hospital-onset CDI (HO-CDI) has not been assessed in a large group of US acute care hospitals (ACHs). METHODS: We examined cross-sectional and temporal associations between rates of hospital-level AU and HO-CDI using data from 549 ACHs. HO-CDI was defined as a discharge with a secondary International Classification of Diseases, Ninth Revision, Clinical Modification code for CDI (008.45), and treatment with metronidazole or oral vancomycin > 3 days after admission. Analyses were performed using multivariable generalized estimating equation models adjusting for patient and hospital characteristics. RESULTS: During 2006-2012, the unadjusted annual rates of HO-CDI and total AU were 7.3 per 10 000 patient-days (PD) (95% confidence interval [CI], 7.1-7.5) and 811 days of therapy (DOT)/1000 PD (95% CI, 803-820), respectively. In the cross-sectional analysis, for every 50 DOT/1000 PD increase in total AU, there was a 4.4% increase in HO-CDI. For every 10 DOT/1000 PD increase in use of third- and fourth-generation cephalosporins or carbapenems, there was a 2.1% and 2.9% increase in HO-CDI, respectively. In the time-series analysis, the 6 ACHs with a ≥30% decrease in total AU had a 33% decrease in HO-CDI (rate ratio, 0.67 [95% CI, .47-.96]); ACHs with a ≥20% decrease in fluoroquinolone or third- and fourth-generation cephalosporin use had a corresponding decrease in HO-CDI of 8% and 13%, respectively. CONCLUSIONS: At an ecologic level, reductions in total AU, use of fluoroquinolones, and use of third- and fourth-generation cephalosporins were each associated with decreased HO-CDI rates. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Authors: Alice Y Guh; Yi Mu; Lisa G Winston; Helen Johnston; Danyel Olson; Monica M Farley; Lucy E Wilson; Stacy M Holzbauer; Erin C Phipps; Ghinwa K Dumyati; Zintars G Beldavs; Marion A Kainer; Maria Karlsson; Dale N Gerding; L Clifford McDonald Journal: N Engl J Med Date: 2020-04-02 Impact factor: 91.245
Authors: Ying P Tabak; Arjun Srinivasan; Kalvin C Yu; Stephen G Kurtz; Vikas Gupta; Steven Gelone; Patrick J Scoble; L Clifford McDonald Journal: Infect Control Hosp Epidemiol Date: 2019-09-16 Impact factor: 6.520
Authors: José Francisco García-Rodríguez; Belén Bardán-García; Pedro Miguel Juiz-González; Laura Vilariño-Maneiro; Hortensia Álvarez-Díaz; Ana Mariño-Callejo Journal: Antibiotics (Basel) Date: 2020-12-26
Authors: Shelley S Magill; Erin O'Leary; Susan M Ray; Marion A Kainer; Christopher Evans; Wendy M Bamberg; Helen Johnston; Sarah J Janelle; Tolulope Oyewumi; Ruth Lynfield; Jean Rainbow; Linn Warnke; Joelle Nadle; Deborah L Thompson; Shamima Sharmin; Rebecca Pierce; Alexia Y Zhang; Valerie Ocampo; Meghan Maloney; Samantha Greissman; Lucy E Wilson; Ghinwa Dumyati; Jonathan R Edwards Journal: Clin Infect Dis Date: 2021-05-18 Impact factor: 9.079
Authors: Katherine E Goodman; Sara E Cosgrove; Lisa Pineles; Laurence S Magder; Deverick J Anderson; Elizabeth Dodds Ashley; Ronald E Polk; Hude Quan; William E Trick; Keith F Woeltje; Surbhi Leekha; Anthony D Harris Journal: Clin Infect Dis Date: 2021-07-15 Impact factor: 20.999
Authors: Nasia Safdar; Vishala Parmasad; Roger Brown; Pascale Carayon; Alexander Lepak; John C O'Horo; Lucas Schulz Journal: BMJ Open Date: 2021-06-29 Impact factor: 2.692